Epilepsy Drugs Market Share, Size, Global Insights and Future Outlook

Summary

Technavio Announces the Publication of its Research Report – Global Epilepsy Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global epilepsy drugs market: Eisai, GSK, Pfizer, and UCB.

Other Prominent Vendors in the market are: Acorda Therapeutics, Alexza Pharmaceuticals, Aprecia Pharmaceuticals, Aurobindo Pharma, Biscayne Pharmaceuticals, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, D-Pharm, F. Hoffmann-La Roche, Grupo Ferrer Internacional, GW Pharmaceuticals, Insero Health, INSYS Therapeutics, Janssen Pharmaceuticals, Ligand Pharmaceuticals, H. Lundbeck, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda, Neurelis, Nobelpharma, Novartis, Orphelia Pharma, SAGE Therapeutics, SciFlour, Sedpr Pharmaceuticals, Shire, SK Biopharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals (US), Supernus Pharmaceuticals, Takeda, Turing Pharmaceuticals, Upsher-Smith, Valeant Pharmaceuticals, and Zogenix.

”

Browse Detail Report With TOC @

https://marketreportscenter.com/reports/319887/global-epilepsy-drugs-market-2016-2020

Commenting on the report, an analyst from Technavio’s team said: “A trend which will boost market growth is the reformulation of marketed drugs. Drug delivery systems such as dispersible and film-coated tablets increase the efficacy of medicines either by increasing the bioavailability of the drug or by expanding patient compliance. This reformulation results in products with improved safety and efficacy profiles and provides an opportunity for drug manufacturers to extend the term of their drug's patents, delaying the market entry of generics. For instance, UCB, Pfizer, and GSK developed film-coated tablets of Keppra, Neurontin, and Trobalt, respectively. Film-coated tablets offer specific properties such as taste-masking, moisture and light protection, superior product appearance, and mechanical resistance.”

According to the report, a key growth driver is the tentative...